Celgene Corporation/Abraxis BioScience, Inc. Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regard to Celgene’s pending acquisition of Abraxis Bioscience, Inc. (NASDAQ: ABII).